Introduction
Treatment of acute myelogenous leukemia (AML) in the elderly has consistently demonstrated poor outcomes, with complete remission rates of 45-55% and only 10-15% overall survival at 4 years. 1 In the relapsed setting, these results are significantly inferior. 1,2 A higher incidence of intrinsic drug resistance in leukemia blasts, potentially mediated by the high frequency of P-glycoprotein (Pgp) expression may partially account for these poor clinical outcomes. 3 Mutations and abnormal expression of RAS genes, especially N-RAS, are detected in between 15 and 90% of these cancers. 4 RAS oncoproteins play a critical role in intracellular signaling, cell proliferation and malignant transformation. Farnesylation of RAS, the first and most critical step in the post-translational modification of RAS, is catalyzed by the enzyme farnesyl transferase (FT). 5 Prevention of RAS processing inhibits a cascade of downstream phosphorylation events, critical to the survival of hematopoietic and cancerous cells. 6 Thus, farnesyl transferase inhibitors (FTIs) are an interesting potential therapeutic option for use in AML.
Although FTIs were originally conceived as targeting mutant RAS function in cancer, the observation that a broad range of human cancer cells are susceptible to FTI therapy independently of RAS mutation status led to the identification of other proteins that may be targets for these compounds. 7, 8 FTIs block anchorage-independent growth of human tumor cell lines, yet there is no correlation between this biological effect and the presence of RAS mutations. 8 These anti-transforming effects of FTIs may be mediated by alteration of farnesylated Rho proteins, which are involved in the regulation of cytoskeleton organization and cell adhesion. 9 Other non-Ras proteins thought to be substrates for FT, include the nuclear lamins and protein tyrosine phosphatases, including components of the phosphoinositide 3-kinase (PI 3 k)/Akt pathway. 10, 11 FTIs may also be active in cells where continuous activation of RAS protein occurs as a result of constitutive upstream growth factor activation.
Recently, lonafarnib (Sarasart, SCH66336, Schering-Plough, Kenilworth, NJ, USA), a tricyclic compound that is a potent FTI, has been shown to be a potent inhibitor of Pgp in fibroblast cell lines and exhibits synergy when coadministered with chemotherapy agents that are substrates of Pgp. Tipifarnib (Zarnestrat, R115777, Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA) is an imidazole-containing heterocyclic FTI, which inhibits the growth of several tumor cell lines, including those that contain either the wild-type or mutant Ras gene. [10] [11] [12] Tipifarnib has demonstrated anti-proliferative effects on cultured AML cells and HL-60 leukemia cells, leading to clinical evaluation in patients with acute leukemia (Lancet JE et al. Blood 1999; 94: 149, abstract).
The promising results of tipifarnib in patients with myeloid leukemia along with the suggestion that FTIs may inhibit Pgpmediated drug efflux, a major factor contributing to chemotherapy resistance in patients with AML, led to the current investigations. The objective of this study was to determine whether tipifarnib has Pgp-modulating activity and to evaluate its anti-proliferative effects on human leukemia cell lines when combined with DNR, an anthracycline that is both a substrate of Pgp and a standard chemotherapeutic agent for AML. To identify a possible dual targeting mechanism with the combination of tipifarnib and anthracycline, we evaluated the inhibition of farnesylation as well as activation of the downstream effector protein, extracellular signal-regulated kinase (ERK), by tipifarnib in the presence and absence of DNR. 
Materials and methods

Reagents
Cell lines
The CCRF-CEM clone 30 cell line, a human acute T-lymphoblastic leukemia cell line overexpressing human Pgp, was a generous gift from Doug Olsen at the National Institutes of Health (NIH). The KG1a human acute T-myeloid leukemia cell line was from American Type Culture Collection. Both cell lines were grown in Rosewell Park Memorial Institute (RPMI) 1640 medium with 10% FBS, and were maintained at 371C. for 2-3 days before replacement of their media.
Flow cytometric analysis of Pgp-mediated efflux using rhodamine 123 and DNR Fluorescence measurements of individual cells were performed using a Becton Dickinson FACScalibur fluorescence-activated cell sorter (FACS) (San Jose, CA, USA), equipped with an ultraviolet argon laser (excitation at 488 nm, emission at 530/30 and 570/30 nm band-pass filters). Analysis was gated to include single cells on the basis of forward and side light scatter and was based on acquisition of data from 5000 cells. Log fluorescence was collected and displayed as single-parameter histograms. A direct functional assay for the Pgp efflux pump in viable cells was performed with the flow cytometer. 13 The cells were washed and resuspended in the appropriate media at a concentration of 6 Â 10 6 cells/ml. Aliquots of 50 ml of the cell suspension were transferred to plastic tubes containing 0.95 ml of incubation media with a fluorescent Pgp substratemarker (RDN or DNR) and FTI. In the accumulation phase, cells were incubated in the presence or absence of tipifarnib (at final concentrations of 0.5, 1.0, 2.0, 3.0 or 4.0 mM) or 100 mM verapamil (positive control), with 10 mM RDN or DNR at 0.2 or 2.0 mM for 30 min at 371C and 5% CO 2 . After centrifugation (300 g for 3 min at 41C), and removal of the supernatant, the cells were reincubated in the presence or absence of tipifarnib (at the same final concentrations stated previously) or 100 mM verapamil, without RDN or DNR for an additional 30 min at 371C and 5% CO 2 (the efflux phase). After final centrifugation (300 g for 3 min at 41C), the supernatant was removed. Cold Hanks' buffer was then added to each tube, and the cell suspension was transferred to FACS tubes that were placed on ice until analysis. All experiments were performed in triplicate.
Calculation of relative fluorescence
The DNR and RDN fluorescence intensity of individual cells was recorded as histograms. The mean fluorescence intensity of 5000 cells was used as a comparison among different experimental conditions. Verapamil 100 mM was selected as a positive control because it can completely inactivate the efflux pump. Relative fluorescence was used for quantification of the effects of different concentrations of tipifarnib on transport. 13 The relative fluorescence (% inhibition) represents a ratio obtained through the formula
Relative Fluorescence
¼
Fluorescence of sample geometric median Fluorescence of no drug sample geometric median Â100
To compare samples using different fluorescent markers, Pgp inhibition was also expressed as the percent of verapamil inhibition using the formula:
Percent of Verapamil inhibition ¼ Fluorescence of sample geometric median Fluorescence of verapamil sample geometric median Â100
Cell viability assays MTT assays. The MTT assay was performed as described previously. 12 Cells were plated in triplicate at 5-7.5 Â 10 3 cells/ well in 96-well plates. The cells were then incubated at 371C for 24 h. Cells were then exposed to DNR alone (0.02, 0.2 or 2.0 mM), tipifarnib alone (0.5, 2.0, and 4.0 mM) and all possible combinations using the aforementioned drug concentrations. Proliferation was assayed at 48 h. The mean was calculated for each concentration and combination of drugs. Means and s.d. were generated from three to four independent experiments and reported as the percentage of growth versus control. Cell proliferation curves were derived from these data, and regression lines were generated in Microsoft Excel. To calculate the doses with 50% inhibition of proliferation (D m or IC 50 values), data were analyzed by the median effect method. Synergy was evaluated using the isobolographic method of Chou and Talalay 14 (Calcusyn, Biosoft, Ferguson, MO, USA) by simulations of different multiple levels of inhibition.
Apoptosis detection FACS using PI and YO-PRO-1
s Dyes. Cells were seeded at 0.5-1. 0 Â 10 6 /ml into six-well plates and allowed to grow for 24 h in 2 ml RPMI medium. Tipifarnib and/or DNR was then added at appropriate concentrations and cells allowed to grow for 48 h. Following drug exposure, cells were washed in cold phosphate-buffered saline (PBS) and centrifuged for 5 min at 300 g. Samples were then analyzed using the Vybrant Apoptosis Assay Kit #4 (Molecular Probes, Eugene, OR, USA). 15 Cells were resuspended in 1 ml cold PBS and 1 ml of the YO-PRO-1 s and PI dyes were added to each tube. YO-PRO-1 s and only PI controls were run as well and used to set the flow parameters. Cells were incubated on ice for 30 min and then assayed on a Coulter EPICS-XL-MCL analyzer. Cell populations were separated into three groups: live cells showed a low level of fluorescence, apoptotic cells showed green fluorescence (YO-PRO-1) s and necrotic cells showed both red and green fluorescence (PI & YO-PRO-1 s ); 10 000 individual events were assayed. The apoptotic index was calculated by dividing the number of apoptotic cells by the total number of cells. All observations were repeated in triplicate. The same method was used to evaluate the effects of the FTI-inactive enantiomer of R115777, R115776.
Poly ADP-ribose Polymerase (PARP) cleavage. Cells were seeded at 0.5-1.0 Â 10 6 /ml into six-well plates and allowed to grow for 24 h in 2 ml RPMI medium. Tipifarnib and/or DNR were then added at appropriate concentrations and cells were allowed to grow for 48 h. Following drug exposure, cells were washed in cold PBS and centrifuged for 5 min at 300 g. Two hundred microliters of radioimmunoprecipitation assay buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) in PBS) supplemented with a protease inhibitor cocktail (Calbiochem, San Diego, CA, USA) and 1 mM phenylmethylsulphonylfluoride was added to each cell pellet. Lysates were incubated on ice for 30 min and then centrifuged at 10 000 g for 10 min at 41C. The supernatants were removed to new tubes and protein quantified using the Bradford assay (BioRad, Hercules, CA, USA). Equal amounts of protein were separated on 10% Tris-HCl Ready gels (Biorad, Hercules, CA, USA) and transferred to polyvinylidene fluoride (PVDF) membranes for Western blot analysis. Detection of PARP cleavage was confirmed by use of a rabbit polyclonal antibody that detected both the cleaved and uncleaved PARP protein FT inhibition assays Farnesylation of HDJ-2. The chaperone protein HDJ-2 is a polypeptide that undergoes farnesylation-dependent processing and, therefore, demonstrates a mobility shift when FT is inhibited. 16, 17 Thus, serial measurement of farnesylated and unfarnesylated HDJ-2 serves as a marker of FT inhibition. 18 Cells were prepared as outlined in the above paragraph. Cell lysates were prepared as previously described. 19 Aliquots of cellular protein were subjected to electrophoresis on 4-20% Tris-HCl Ready Gels (Biorad, Hercules, CA, USA), transferred to a PVDF membrane and probed with mouse anti-HDJ-2 (Neomarkers, Fremont, CA, USA) using techniques previously described. 19 Membranes were washed and probed with an anti-mouse IgG-HRP secondary antibody, and developed by enhanced chemiluminescence (Amersham, USA). The farnesylated form of HDJ-2 was identified by faster gel migration patterns.
Phosphorylation of signaling intermediates ERK1/ ERK2. Processed Ras proteins trigger a cascade of phosphorylation events through sequential activation of signaling intermediates, which include Raf, mitogen-activated protein kinase (MAPK)/extracellular responsive kinase (ERK)-1, and ERKs. Thus, the phosphorylation of these proteins serves as downstream markers for a functional FT, and therefore, the presence of phosphorylated ERKs was assessed. Cells were seeded into sixwell plates and allowed to grow for 24 h in 2 ml RPMI medium. After initial incubation, cells were exposed to 0.2 mM DNR alone, tipifarnib alone at 0.5 or 2.0 mM, and 0.2 mM DNR plus tipifarnib at 0.5 or 2.0 mM for 48 h. After 4-20% SDSpolyacrylamide gel electrophoresis, protein extracts were transferred to a PDVF membrane, and probed with rabbit anti-ERK1/ERK2 antibody (Cell Signaling Technologies, Beverly, MA, USA). Donkey anti-rabbit HRP secondary antibody (Amersham, Piscataway, NJ, USA) allowed visualization by enhanced chemiluminescence (Amersham, Piscataway, NJ, USA). Phosphorylated forms were identified by their slowed gel migration.
Statistical Analysis. Data are expressed as means þ s.d.
Analysis was performed using analysis of variance, unpaired t-test and Mann-Whitney U-test, as appropriate, using Graphpad Prism 4 (GraphPad Software Inc. San Diego, CA, USA). Po0.05 was considered statistically significant. For the t-tests of daunorubucin retention (Figure 1 ), the value of 1.0 was used as the comparison point. In Table 1 , the retention value for verapamil was used as the comparison point for t-tests. In Figure 3 , the statistical comparisons were between treated cells and controls (no drug).
Results
Pgp inhibition
Flow cytometry was used to assess the effects of tipifarnib on Pgp-mediated anthracycline efflux. As fluorescent substrates of Pgp, DNR and RDN serve as markers for active transport function by measurement of retained fluorescence in the cell. 15 Herein, we demonstrate that tipifarnib effectively inhibited the Pgp-dependent transport of DNR (2.0 mM) in the human leukemia cell line CCRF-CEM in a dose-dependent manner (IC 50 o 0.5 mM), corresponding to approximately 45% of the verapamil inhibition (Figure 1 ). The retention of DNR by tipifarnib was significantly greater than untreated cells at all concentrations tested (0.5-4 mM) (Po 0.01). Although DNR at a concentration of 2.0 mM exhibits optimal fluorescence enabling discrimination in the potency of inhibition for most Pgp inhibitors, we also pursued clinically relevant concentrations of DNR (0.2 mM). 11, 17 At this concentration, the effects of tipifarnib on Pgp-mediated in CCRF-CEM cells were more modest, however still statistically significant at concentrations X0.5 mM (Po 0.01). In a human AML cell line overexpressing Pgp, (KG1a), similar results were demonstrated (data not shown).
To evaluate the relationship between inhibition by tipifarnib and the physicochemical characteristics of the Pgp substrate, we also assessed the retention of RDN, which has a different binding site than DNR on the Pgp transporter. 15 The retention of RDN in the presence of tipifarnib was strikingly different, Tipifarnib (Table 1) . Further, to confirm the independence of the Pgp inhibitory from the FTI effects of tipifarnib, we performed the same experiments with the FTIinactive enantiomer of tipifarnib, R115776. This compound retained the ability to reverse Pgp-mediated DNR efflux, perhaps with slightly more potency than tipifarnib (Table 1 ). These results demonstrate that the structural characteristics that confer Pgp-reversal activity by tipifarnib are distinct from those that mediate inhibition of FT activity.
Proliferation assays
Next, the CCRF-CEM cells were assessed for sensitivity to tipifarnib, DNR and combination of both agents. Tipifarnib and DNR as single agents demonstrated modest, dose-dependent reductions (when compared to untreated cells) in the cellular proliferation of both CCRF-CEM and KG1a cells at 48 h. Assessment of the combinatorial activity of tipifarnib and DNR was performed using the isobolographic method of Chou and Talalay 14 (Figure 2a-d) . Interestingly, synergistic drug activity was apparent as evidenced from the normalized isobolograms for drug combinations in the CCRF-CEM cell line (Figure 2a) . The FTI-inactive enantiomer of tipifarnib, R115776., also exhibited clear synergy when combined with DNR ( Figure 2b ). Similar data was obtained with the KG1a cells (Figure 2c-d) .
Apoptosis
To determine whether the combination of tipifarnib and DNR were associated with cell death, apoptosis was assessed by flow cytometry. CCRF-CEM cells were exposed (48 h) to tipifarnib alone (0.5 and 2.0 mM) and in combination with 0.2 mM DNR (Figure 3a) . At 48 h, both single-agent tipifarnib and DNR, demonstrated no significant induction of apoptosis of CCRF-CEM cells compared to untreated cells. The combination of DNR (0.2 mM) with the intermediate (2 mM) concentration of tipifarnib demonstrated an increase in apoptosis that is statistically significant. Interestingly, in the KGIa cells, there were more pronounced effects resulting in enhancement of apoptosis at both low (0.5 mM) and intermediate (2 mM) concentrations of tipifarnib (Figure 3a) . These effects were retained with the FTI-inactive enantiomer, R115776 (Figure 3b ). 
Farnesylation of HDJ-2
Next, we confirmed the FT-inhibitory effects of tipifarnib, DNR and the combination using a gel-shift assay for processing of the human chaperone protein, HDJ-2. As depicted in Figure 5 , after exposure to tipifarnib for 48 h, there appeared to be a dosedependent inhibition of farnesylation as demonstrated by a progressive shift of HDJ-2 to the unprocessed form in CCRF-CEM and KG1a cells. By contrast, exposure of either cell line to 0.2 mM DNR alone did not result in a gel shift of HDJ-2. Interestingly, the combination of 2 mM of tipifarnib and DNR 0.2 mM resulted in almost complete conversion of HDJ-2 to the unprocessed form in the KG1a cells. These data indicate that DNR does not interfere with the inhibitory effect of tipifarnib on FTase, and that the combination may actually enhance this effect in some cells.
Phosphorylation of signaling intermediate ERK1/ERK2
To assess the downstream effects of FT inhibition by tipifarnib alone or in combination with DNR, activation of ERK (a downstream effector of the Ras/Raf/MAPK pathway) was evaluated by immunoblotting. 20 Phosphorylated ERK was evaluated after 48 h of exposure to DNR alone, increasing concentrations of tipifarnib, or the combination of DNR and tipifarnib ( Figure 6 ). DNR was without effect on phospho ERK, whereas single-agent tipifarnib, as expected, decreased phospho ERK in a dose-dependent manner. Interestingly, the combination of DNR and R11 decreased phospho ERK compared to that observed with single-agent DNR, but not to same extent as single-agent R11. Total ERK 1/2 level did not change significantly with any of the exposures (data not shown).
Discussion
Despite multiple advances in the understanding of mechanisms of leukemogenensis, AML still remains a devastating disease. This is especially true for the elderly, where associated comorbid conditions and intrinsic resistance to conventional treatment with combination chemotherapy are major limiting factors in the development of new treatment combinations, ultimately limiting improvement of survival in this disease. Recent studies suggest that single-agent tipifarnib is an active agent in the treatment of AML and has a very tolerable side effect profile. 18, 21 Thus, development of new regimens incorporating tipifarnib may result in improvement in the outcome of patients with AML without significantly adding intolerable or life-threatening toxicities. In this study, we set out to determine whether tipifarnib exhibits Pgp-reversal properties, based upon previously published data with lonafarnib, a structurally unrelated FTI. Intrinsic drug resistance is thought to be a major factor in the resistance of leukemia blasts to chemotherapy. 12 Thus, we assessed the combinatorial effects of tipifarnib plus DNR on cell proliferation, apoptosis, FT inhibition and phosphorylation of ERK1/2 in two human leukemia cell lines which overexpress Pgp.
In this report, we demonstrate that tipifarnib, an orally active FTI, 21 is also able to inhibit Pgp-mediated efflux of DNR in a dose-dependent manner. Moreover, tipifarnib demonstrated dose-dependent inhibition of cellular proliferation and exhibited cytotoxic synergism when combined with DNR, which appears to be associated with increased cellular apoptosis. FT enzyme inhibition was evaluated and the accumulation of unprocessed HDJ-2 indicated that tipifarnib-mediated post-translational protein processing is not affected when combined with DNR. The Pgp-modulating effects of tipifarnib are independent of the FTI effects, as demonstrated by equipotent Pgp inhibition by R115776, the FTI-inactive enantiomer of tipifarnib. These results suggest that Pgp represents an additional therapeutic target of tipifarnib, in addition to farnesyl transferase, thus indicating a dual mechanism of action that may be particularly relevant in the treatment of poor risk AML. In this study, we initially wanted to determine whether tipifarnib had Pgp-inhibiting properties similar to lonafarnib, another FTI with a similar dual mechanism of action. 12 In CCRF-CEM cells, tipifarnib demonstrated half-maximum inhibition (IC 50 ), when compared to verapamil, of Pgp-mediated DNR efflux as concentrations less than 1 mM. At clinically relevant concentrations of DNR (0.2 mM), the IC 50 of tipifarnib was less than 3 mM. This difference in potency between the two concentrations of DNR is likely due to the saturation of the DNR-binding site at the Pgp molecule. 22 Our results are very similar to those obtained with lonafarnib, which demonstrated an IC 50 of 2.7 mM, 12 although the DNR concentration reported was not clear. These results coupled with the results from pharmacokinetic studies of tipifarnib in patients with AML that received tipifarnib 600 mg twice daily demonstrate that tipifarnib is able to inhibit Pgp-mediated DNR efflux at clinically relevant concentrations. 18, 23 For example, in these studies the C max and C min varied between 3 and 3.5 mM and 1.5-0.5 mM. 18, 23 Although preclinical data indicate that the plasma protein binding of tipifarnib is 99.3%, 23 in vivo pharmacokinetic data suggest that these concentrations inhibit FT activity and result in antitumor effects. 18 Despite these similarities, tipifarnib and lonafarnib are distinct molecules that are not structurally related. Recent photoaffinitylabeling studies suggest there are at least four different drugbinding sites to Pgp. 24, 25 The interaction of these sites may account for the wide range of functionally and structurally distinct Pgp modulators and substrates. Despite the fact that most Pgp substrates share certain chemical features, Pgp modulators have been grouped into seven structural categories. 25 Lonafarnib is a structural analog of a calmodulin antagonist, whereas tipifarnib is a heterocyclic imidazolecontaining compound that is similar in structure to the azole antifungals, which are also Pgp inhibitors. 25, 26 Therefore, despite possessing both Pgp and FT inhibitory activities, these compounds are unlikely to inhibit Pgp function through interaction at the same drug-binding site.
Interestingly, we found that the combination of tipifarnib and DNR was synergistically active against both Pgp-expressing leukemia cell lines used in this study. Tipifarnib, as a single agent, has been shown to inhibit proliferation in several different leukemia cell lines in vitro. 27 Enhanced antitumor activity has been reported in preclinical cancer models when tipifarnib was used in combination taxanes, cisplatin and gemcitabine. 28 Although the mechanism of synergy between tipifarnib and DNR are not clear, several studies have shown that the intracellular concentration of DNR in leukemic cells as an important determinant of cytotoxicity. 29, 30 Thus, we speculate that increase intracellular concentration, from tipifarnibmediated Pgp inhibition, coupled to the antiproliferative effects of tipifarnib alone may be responsible for the synergistic action of these two agents against CCRF-CEM and KG1a cells.
Initially conceived as targeting mutant RAS function in tumor cells by preventing post-translational RAS farnesylation, FTIs are now known to modulate, through farnesylation inhibition, a number of cancer-associated proteins. In this study, the accumulation of unprocessed HDJ-2, an ubiquitously expressed farnesylated protein, was used to assess the FTI effects of tipifarnib. The combination of tipifarnib and DNR resulted in a substantial shift of HDJ-2 to the unfarnesylated form. Because DNR does not appear to interfere with FT inhibition by tipifarnib, coadministering these agents targets both cellular proliferation and Pgp-dependent drug efflux. Tipifarnib alone, as expected, decreased phosphorylation of ERK, whereas DNR alone seemed to be without effect. However, the phosphorylation of ERK, although being decreased by the combination of both drugs compared to single agent DNR, was greater than that of single-agent tipifarnib. This result may be due in part to previous findings that chemotherapeutic agents induce prosurvival pathways that include the ERKs, 31, 32 and be reflective of differential modulation of ERK activation by DNR and tipifarnib when in combination. Nonetheless, the data with phospho ERK is suggestive that this signaling pathway is not directly associated with the synergistic antiproliferative effects we report here.
Several recent studies of the use of single-agent tipifarnib in adults with high-risk leukemias have been reported 18 (Lancet JE et al. Blood 2000; 102: 176, abstract). Overall response rates were approximately 30% and complete remission rates ranged between 6 and 21% 18 (Lancet JE et al. Blood 2000; 102: 176, abstract). FT enzyme inhibition was observed in the majority of patients; however, a relationship between FT inhibition and clinical response could not be established. Interestingly, N-RAS mutations were not detected in any of the bone marrow samples analyzed. 18 Overall, tipifarnib was well-tolerated and demonstrated antileukemic activity, even in heavily pretreated patients with AML (Lancet JE et al. Blood 2000; 102: 176, abstract). As mentioned previously, the high frequency of Pgp expression 3 and abnormal expression of RAS gene 4 may contribute to the poor outcomes in the treatment of patients with AML. Despite ambiguous results on the role of FTI as RAS inhibitors, tipifarnib clearly exhibits both in vivo and in vitro antiproliferative effects against leukemic blasts 18 (Lancet JE et al. Blood 2000; 102: 176, abstract). Thus, addition of tipifarnib to current chemotherapeutic regimens for AML may result in enhanced results through its dual FTI and Pgp-reversal activities.
In conclusion, our results indicate that tipifarnib inhibits Pgpmediated anthracycline efflux from a leukemia cell line at clinically relevant concentrations. Coadministration of tipifarnib and DNR inhibits cellular proliferation and induces apoptosis. Thus, based on our results, the mild toxicity profile of tipifarnib as a single agent, 18 and the promising results in Phase I and II studies in high-risk leukemia patients (Lancet JE et al. Blood 2000; 102: 176, abstract), clinical studies evaluating the combination of tipifarnib and anthracycline in patients with AML are ongoing.
